Oak Associates LTD Abb Vie Inc. Transaction History

Oak Associates LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$138.31 - $165.87 $1.64 Million - $1.97 Million	11,858 Added 399.93%	14,823 $2.4 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $1,376 - $1,749	-10 Reduced 0.34%	2,965 $454,000
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $1,023 - $1,126	10 Added 0.34%	2,975 $322,000
Q4 2020 Feb 12, 2021	SELL	$80.49 - $108.67 $1.27 Million - $1.72 Million	-15,829 Reduced 84.22%	2,965 $318,000
Q2 2020 Aug 11, 2020	BUY	$73.37 - $98.18 $1.38 Million - $1.85 Million	18,794 New	18,794 $1.85 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $689,505 - $1.05 Million	-10,690 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$72.13 - $90.25 $272,651 - $341,145	-3,780 Reduced 26.12%	10,690 $946,000
Q2 2019 Aug 09, 2019	BUY	$65.7 - $83.98 $526,914 - $673,519	8,020 Added 124.34%	14,470 $1.05 Million
Q3 2018 Nov 13, 2018	BUY	$88.91 - $98.84 $41,787 - $46,454	470 Added 7.86%	6,450 $610,000
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $93,371 - $110,479	1,040 Added 21.05%	5,980 $554,000
Q2 2017 Aug 18, 2017	BUY	N/A	4,940	4,940 $358,000

3,795

1.28B

13M

9.82M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $353B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Oak Associates LTD , based on Form 13F filings with the SEC.

Stay updated on Oak Associates LTD with notifications on news.